Kinomatic announced it has raised $4 million in seed funding to scale its personalized, opioid-sparing orthopedic surgical approach.
The seed round was led by Waterline Ventures. And the funding will support Kinomatic’s plans to scale its team in critical roles, open a new office, and continue developing its AI-enabled surgical planning platform. The company is focused on optimizing long-term, opioid-sparing outcomes in the pre-operative and recovery phases of total knee and hip replacement surgery.
Founded in 2021, Kinomatic is an AI- and VR-driven orthopedic surgery planning and aftercare company. The company said it has achieved 7x revenue growth over four years, a 5x expansion in provider relationships, and a Net Promoter Score of 85.
Kinomatic’s platform spans the surgical continuum through four core capabilities: custom pre-operative 3D modeling tailored to each patient’s anatomy, VR surgical simulation that enables surgeons to rehearse procedures before entering the operating room, post-operative recovery optimization, and long-term outcomes tracking with concierge-level care.
The company said orthopedic surgery has historically relied on generic alignment parameters that do not fully account for a patient’s unique biomechanics. Kinomatic’s platform combines AI-enabled surgical planning and VR-enabled surgical simulations to help clinicians complete surgeries more quickly and accurately, improve prosthesis sizing accuracy, and accelerate postoperative functional recovery.
The platform analyzes more than two million data points from over 1,000 unique measurements per patient to identify the optimal match from more than 30,000 possible implant configurations. This level of detail is designed to provide biomechanical precision beyond standard 2D templating and one-size-fits-all approaches.
Kinomatic also announced that Dr. Andrew B. Wickline, MD, FAAOS, has joined the company as Chief Medical Officer. Dr. Wickline is a board-certified orthopedic surgeon known for developing advanced patient-centric protocols that accelerate post-operative recovery. He also developed March2aMillion, a national nonprofit initiative focused on reducing opioid dependency in orthopedic surgery through education, surgeon enrollment, and advocacy.
In his new role, Dr. Wickline will focus on enhancing Kinomatic’s post-operative recovery protocols by implementing a new recovery program he developed while researching recovery optimization.
KEY QUOTES:
“Kinomatic is uniting technology and unparalleled patient care to deliver a new gold standard, where every aspect of surgery is optimized, with the goal of a knee or hip that feels so natural that patients forget they ever had surgery. Patients expect more than just ‘good enough’ from their care. Longevity is no longer a fringe concept, and patients having these surgeries are thinking ahead to what the next 20 to 30 years look like.”
Shaun Lea, CEO of Kinomatic
“For too long, recovery has been the forgotten phase of joint replacement. Patients are left to navigate the hardest part of the procedure largely on their own, often with a bottle of opioids as their only tool. What Kinomatic has built changes that equation entirely. By combining precision pre-operative planning with a concierge recovery model built around a patient’s unique anatomy and biology, we can begin to close the gap between a great surgery and a great outcome.”
Dr. Andrew B. Wickline, Chief Medical Officer of Kinomatic
“Total hip and knee replacements are among the fastest-growing surgical categories in the country. Kinomatic focuses on improving recovery outcomes for patients and surgeons. Kinomatic’s platform is built around the patient, providing data and tools that were previously unavailable to their surgeon. The company has partnered with leading surgeons around the country, and is well-positioned for growth within this market.”
Robbie Greenglass, Managing Partner at Waterline Ventures
